KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Free Cash Flow (2016 - 2025)

Biogen (BIIB) has 17 years of Free Cash Flow data on record, last reported at $468.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 35.14% year-over-year to $468.0 million; the TTM value through Dec 2025 reached $2.1 billion, down 24.65%, while the annual FY2025 figure was $2.1 billion, 24.65% down from the prior year.
  • Free Cash Flow reached $468.0 million in Q4 2025 per BIIB's latest filing, down from $1.2 billion in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.2 billion in Q3 2025 and bottomed at -$261.4 million in Q4 2022.
  • Average Free Cash Flow over 5 years is $528.4 million, with a median of $555.2 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: plummeted 133.23% in 2022, then skyrocketed 1469.26% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $786.7 million in 2021, then tumbled by 133.23% to -$261.4 million in 2022, then skyrocketed by 79.84% to -$52.7 million in 2023, then surged by 1469.26% to $721.6 million in 2024, then crashed by 35.14% to $468.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $468.0 million in Q4 2025, $1.2 billion in Q3 2025, and $134.3 million in Q2 2025.